Wird geladen...
Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency
BACKGROUND. The histone deacetylase (HDAC) inhibitor vorinostat (VOR) can increase HIV RNA expression in vivo within resting CD4(+) T cells of aviremic HIV(+) individuals. However, while studies of VOR or other HDAC inhibitors have reported reversal of latency, none has demonstrated clearance of lat...
Gespeichert in:
| Veröffentlicht in: | J Clin Invest |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
American Society for Clinical Investigation
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5531421/ https://ncbi.nlm.nih.gov/pubmed/28714868 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI92684 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|